S tier · elite
Oxytocin is a licensed prescription-only medicine in the UK (five live emc Summaries of Product Characteristics, e.g. PL 01502/0097), is approved in the United States as PITOCIN under NDA 018261, has been on the WHO Model List of Essential Medicines since 1977, and served as the active comparator in a 29,645-woman randomised non-inferiority trial with a hard haemorrhage endpoint. The grade reflects the obstetric evidence base only.
oxytocin
Oxytocin is the endogenous cyclic nonapeptide released from the posterior pituitary that contracts uterine smooth muscle and drives milk ejection. Synthetic oxytocin is one of the oldest and most heavily used licensed medicines in maternity care, indicated for induction and augmentation of labour and for prevention and treatment of postpartum uterine atony and haemorrhage. Its separate reputation as a 'bonding' or 'trust' molecule rests on a distinct intranasal literature in healthy volunteers and psychiatric populations, which its own investigators have documented as unreliable.
the explanation
Oxytocin is the hormone the body makes to squeeze the womb during labour and to release milk during breastfeeding. As a medicine it is given in hospital by injection or drip and is one of the most important drugs in maternity care anywhere in the world. The idea that sniffing it makes people more trusting or affectionate comes from a completely separate line of research, much of which has not held up when the experiments were repeated in larger and better-designed studies.
regulatory status
Licensed prescription-only medicine in the UK, the US and the EU
Oxytocin is a licensed medicinal product and a prescription-only medicine in the United Kingdom. The electronic medicines compendium currently carries five live oxytocin Summaries of Product Characteristics from four companies; the Hameln Pharma product (PL 01502/0097) states its legal status as 'Prescription only medicine' and its section 4.1 indications are exclusively obstetric. In the United States oxytocin is approved and marketed as PITOCIN (oxytocin injection, USP) under NDA 018261. Oxytocin sits in the uterotonics section of the WHO Model List of Essential Medicines and was first added in 1977. Two points the research-peptide market obscures: no intranasal oxytocin product holds a UK marketing authorisation for any indication, and a Syntocinon-branded SmPC no longer appears on the emc at all, although Syntocinon remains the historic UK trade name still used in NHS clinical guidance. Oxytocin is not a controlled drug, does not appear anywhere in the WADA 2026 Prohibited List, and is not a lawful dietary-supplement ingredient: as a prescription-only medicine, lawful supply for human use in the UK requires a prescription.
how it works · proposed mechanism
Oxytocin acts at a single well-characterised G-protein-coupled receptor, the oxytocin receptor, with additional weak activity at vasopressin receptors. In the uterus that receptor pharmacology translates directly into a clinical effect that can be measured with a stopwatch and a blood-loss estimate. In the brain the same receptor is expressed in regions relevant to social behaviour, but the step from receptor expression to a measurable human behavioural effect is where the evidence base breaks down.
Oxytocin receptor signalling in myometrium
Oxytocin binds the Gq/11-coupled oxytocin receptor on uterine smooth muscle, activating phospholipase C, generating IP3 and releasing intracellular calcium, which produces rhythmic contraction of the uterus. This is the mechanism the UK SmPC describes and the basis of every licensed indication.
Third-stage haemostasis
After delivery, sustained tonic contraction of the myometrium mechanically compresses the spiral arterioles of the placental bed. This is why oxytocin prevents and treats postpartum uterine atony and haemorrhage, and why it is a WHO essential medicine rather than a supportive therapy.
Central oxytocin receptors and social behaviour
Oxytocin receptors are expressed in the amygdala, hypothalamus and other regions implicated in social processing, and animal work in monogamous rodents generated the pair-bonding hypothesis. Human work has had to infer central action from peripheral administration, which is a much weaker design than the animal studies it was built on.
The intranasal route is the weak link
All behavioural claims depend on intranasal delivery. Lane and colleagues explicitly list 'poor knowledge of the exact pharmacokinetic properties' of oxytocin alongside statistical and methodological problems as reasons the behavioural literature became unreliable. Without a measurable exposure-response relationship in humans, a null result and an under-dosed result cannot be distinguished.
what’s reported
evidence shape
7 sourcesThe composition of the cited literature by study type. This describes the shape of the evidence, not its quality — and it does not by itself set the grade.
⚠ the catch
Oxytocin's grade rests entirely on obstetrics, and not on anything the research-peptide market sells it for. Every UK and US licensed indication is uterine — induction and augmentation of labour, management of incomplete or missed abortion, use during caesarean section after delivery of the child, and prevention and treatment of postpartum atony and haemorrhage — and no intranasal oxytocin product holds a UK marketing authorisation for anything. The 'bonding hormone' claim comes from a separate intranasal literature whose own investigators have published its unreliability: one laboratory opened its file drawer and disclosed eight studies run between 2009 and 2014 in 453 subjects across 25 paradigms that produced only five publications, of which just one reported a null finding, while a systematic review of interactive intranasal effects concluded that statistical power was 'critically low and unrelated to the rate of significant results' and that replications, when attempted at all, were 'largely unsuccessful'. The trial designed to settle the clinical question randomised 290 children and adolescents with autism for 24 weeks and found a change of −3.7 with oxytocin versus −3.5 with placebo on its primary social-withdrawal endpoint (P=0.61). An S-tier medicine is therefore being marketed on the strength of a claim that would grade D or F on its own.
key published findings
- The UK SmPC for oxytocin lists only obstetric indications — induction and augmentation of labour, management of incomplete, inevitable or missed abortion, use during caesarean section following delivery, and prevention and treatment of postpartum uterine atony and haemorrhage — and states its legal status as 'Prescription only medicine' (PL 01502/0097, Hameln Pharma).
- In the WHO CHAMPION non-inferiority trial (29,645 women, 23 sites, 10 countries) oxytocin was the active comparator: the composite primary outcome occurred in 14.4% of oxytocin recipients versus 14.5% with heat-stable carbetocin (relative risk 1.01, 95% CI 0.95 to 1.06).
- The largest and best-controlled trial of intranasal oxytocin for social functioning (Sikich et al., New England Journal of Medicine 2021; 290 children and adolescents with autism, 24 weeks) found a least-squares mean change of −3.7 with oxytocin versus −3.5 with placebo on the Aberrant Behavior Checklist modified Social Withdrawal subscale (P=0.61), with no significant difference on secondary social-function or IQ outcomes.
- Lane and colleagues opened one laboratory's file drawer: eight intranasal oxytocin studies conducted between 2009 and 2014, covering 13 dependent variables across 25 paradigms in 453 subjects, yielded only five publications, of which one reported a null finding.
- Mierop and colleagues' systematic review of interactive intranasal oxytocin effects in healthy people found effects 'highly heterogeneous', replication mostly not attempted, 'largely unsuccessful' when it was, significance unrelated to sample size, and power 'critically low and unrelated to the rate of significant results'.
- Oxytocin has been on the WHO Model List of Essential Medicines since 1977, listed in the uterotonics section for postpartum haemorrhage.
limitations of the evidence
- Every licensed indication anywhere in the world is obstetric; there is no approved indication in any jurisdiction for social, cognitive, 'bonding' or wellbeing use.
- All behavioural claims depend on intranasal administration, and the pharmacokinetics of central exposure by that route are poorly characterised in humans, so exposure-response cannot be checked and null results cannot be interpreted.
- Reported social-cognition effects are small and heterogeneous, and the field's own systematic reviews report that statistical power was critically low and unrelated to how often results reached significance — the signature of an exploratory literature, not a confirmed one.
- The 24-week autism trial designed to be definitive was null on its primary endpoint and on its secondary social-function and IQ endpoints, removing the strongest clinical rationale for behavioural use.
- Peripherally administered oxytocin is cleared with a plasma half-life of 3 to 20 minutes, so any claimed sustained behavioural effect requires a mechanism other than continued receptor occupancy.
- Because oxytocin is a prescription-only medicine, material offered as a research chemical sits outside the licensed supply chain and carries none of the identity, purity or sterility assurance attached to a marketing authorisation.
documented safety signals
- The UK SmPC warns that prolonged intravenous administration alongside large fluid volumes can cause water intoxication with hyponatraemia; maternal and neonatal hyponatraemia are both listed adverse reactions.
- Excessive exposure causes uterine overstimulation, which the SmPC states may cause foetal distress, asphyxia and death, or lead to hypertonicity, tetanic contractions or rupture of the uterus.
- Cardiac adverse reactions are labelled: tachycardia and bradycardia are common, arrhythmia uncommon, and myocardial ischaemia and QTc prolongation are reported at unknown frequency; rapid intravenous injection may cause acute short-lasting hypotension with flushing and reflex tachycardia.
- Anaphylactic and anaphylactoid reactions are listed as rare, and the SmPC records reports of anaphylaxis in women with known latex allergy, attributed to structural homology between oxytocin and latex proteins.
- Intranasal trials have generally reported adverse-event incidence and severity similar to placebo, including over 24 weeks in the 290-participant autism trial; a benign tolerability profile in that setting says nothing about efficacy and should not be read as endorsement of unlicensed use.
identity
| full name | Oxytocin, the endogenous cyclic nonapeptide neurohypophysial hormone (synthetic oxytocin as a licensed injectable medicine) |
| category | Hormonal |
| modality | peptide |
| formula | C43H66N12O12S2 |
| molar mass | 1007.2 g/mol |
| cas | 50-56-6 |
| half-life | Plasma half-life of 3 to 20 minutes, per section 5.2 of the UK Summary of Product Characteristics |
| sequence | Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly-NH2, cyclised by a disulfide bridge between Cys1 and Cys6 (CYIQNCPLG, C-terminal amide) |
laboratory handling
| storage | Handle lyophilised oxytocin as a moisture- and oxidation-sensitive disulfide peptide: keep the sealed vial frozen, desiccated and protected from light, and allow it to equilibrate to room temperature before opening so that atmospheric moisture does not condense onto the powder. Once in aqueous solution, hold refrigerated between 2 °C and 8 °C, protect from light, and aliquot to avoid repeated freeze-thaw cycles, which accelerate deamidation and disulfide scrambling. Licensed oxytocin injection is itself stored between 2 °C and 8 °C. |
| solubility | Freely soluble in water and in aqueous buffers; licensed injectable presentations are simple aqueous solutions. The Cys1-Cys6 disulfide bridge makes the molecule sensitive to reducing agents and to alkaline conditions, and solutions are conventionally held slightly acidic for stability. Avoid oxidising conditions and organic solvent systems that promote aggregation or adsorption to labware. |
| co-studied with | There is nothing to stack: the licensed use of oxytocin is a single-agent, monitored hospital obstetric intervention, and no controlled study supports combining it with other peptides for behavioural, social or performance purposes. |
Handling information describes laboratory practice for a research reagent. It is not a preparation guide for use in humans.
the receipts
7 citedelectronic medicines compendium (emc), Hameln Pharma Ltd, PL 01502/0097 · 2020 · official
DailyMed, US National Library of Medicine / Par Health USA · 2024 · official
WHO Electronic Essential Medicines List (eEML) · 2023 · official
Journal of Neuroendocrinology 28(4) · 2016 · peer-reviewed
New England Journal of Medicine 379(8):743-752 · 2018 · randomized
New England Journal of Medicine 385(16):1462-1473 · 2021 · randomized
Perspectives on Psychological Science 15(5):1228-1242 · 2020 · systematic review
others in Hormonal